-1752954591090.webp&w=3840&q=75)
2025 NOSCM | Immunotherapy in Head and Neck Cancers
Overview
Dr. Robert Haddad shared advances in head and neck cancer, highlighting perioperative pembrolizumab's FDA approval. Unlike past trials, Keynote 689 showed improved event-free survival. Nivo Post-Op also benefited high-risk patients, underscoring multidisciplinary care's role in treatment progress.
Target Audience
Physicians
Nurses
Pharmacists
Physician Associates
This material is non‑CME, no credits are available, and a certificate will not be provided upon completion.
Faculty
Robert Haddad, MD
Date of Release
July 20th, 2025
-1755988066641.webp&w=3840&q=75)
-1755987918967.webp&w=3840&q=75)